NBIX - What's Going On With Neurocrine Biosciences Stock Today? | Benzinga
Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).
CAH is a group of genetic conditions limiting hormone production in the adrenal glands. These glands produce hormones your body needs to function properly.
Also Read: Full story available on Benzinga.com